SEC Tracker
Get the app
BMY · XBRL financial data

Bristol-Myers Squibb Company financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (BMY's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue11,477*11,86512,20111,89212,342*11,20112,26912,22212,502*11,48912,97313,069
Cost of goods and services sold2,745*2,9323,2672,9574,812*3,0333,3723,4354,097*3,4213,7264,146
Research and development2,478*2,6952,8992,3743,191*2,2572,5802,5282,586*2,6492,9592,365
Selling, general and administrative2,073*2,3671,9281,9832,136*1,5841,7131,7892,181*1,6171,8261,699
Interest income145*1838794114*138139161148*104101118
Interest expense316*425521505496*494485480432*411407403
Other income (expense)371*(81)(273)(234)(305)*(339)(494)10851*(32)61(307)
Income tax expense (benefit)(88)*392(398)46199*509460919384*561770374
Net income (loss)1,762*(11,911)1,6801,21172*2,4561,3102,2011,087*2,6773,3172,162
Earnings per share, basic USD per share0.87*(5.89)0.830.600.04*1.210.641.080.53*1.311.621.06
Earnings per share, diluted USD per share0.87*(5.89)0.830.600.04*1.200.641.080.53*1.311.621.05
Weighted average shares, basic millions of shares2,028*2,0232,0272,0282,030*2,0312,0352,0362,034*2,0382,0422,043
Weighted average shares, diluted millions of shares2,034*2,0232,0292,0312,025*2,0402,0382,0392,039*2,0472,0482,053

Balance sheet

CSV

Fiscal quarters (BMY's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents11,4649,3306,2937,89010,34610,87512,59915,72610,2099,5748,7229,574
Marketable securities8163403602045139071,0047764649122,3453,007
Marketable securities, non-current364367357324320344346406396366397378
Accounts receivable8,8828,8269,7469,3179,0129,0639,7119,6249,5927,9469,0779,192
Inventory2,6622,9853,0773,3322,5572,6662,7372,7582,6902,7562,7372,704
Total current assets31,77028,66926,89028,07529,78030,78333,22235,63029,39027,20828,57929,767
Property and equipment, net6,6466,7506,8456,9037,1367,2137,3737,3497,5437,6587,7917,971
Right-of-use asset1,3901,4361,3161,3481,2241,2151,2761,6041,5821,5281,4861,480
Goodwill21,16921,73821,73221,75121,71921,73721,77621,74521,75421,74021,74021,735
Total assets95,15999,03194,64693,67092,60392,42794,67696,88990,03886,47687,63488,772
Accounts payable3,2593,5393,7513,4693,6024,0025,4274,2883,5754,2344,1584,628
Commercial paper02,991266—————————
Current portion of long-term debt2,8732,8733,0928731,8283,3494,4754,2481,9771,988768768
Total current liabilities22,26225,82223,26522,63823,77424,07027,52828,13623,41719,15818,65918,753
Long-term debt36,65349,48748,85848,67447,60346,15744,47044,46942,85042,15242,09341,849
Lease liability, non-current1,5301,5631,4381,4831,3701,3561,5501,8491,8261,7701,7261,713
Total liabilities65,67482,48377,57776,47076,21574,97977,18778,28971,53366,37465,31565,368
Retained earnings28,76615,64016,10316,09714,91216,10616,15417,09316,89618,28720,31621,190
Total stockholders' equity29,43016,49017,01517,14216,33517,38917,43518,55218,47320,06822,31923,404
Total liabilities and equity95,15999,03194,64693,67092,60392,42794,67696,88990,03886,47687,63488,772
Common shares outstanding (cover page) millions of shares2,0222,0272,0272,0282,0292,0352,0352,0362,0362,0422,0432,044

Cash flows

CSV

Fiscal quarters (BMY's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)1,762*(11,911)1,6801,21172*2,4561,3102,2011,087*2,6773,3172,162
Stock-based compensation127*133125*129*120*144137*139*133*146135*138*
Depreciation and amortization2,464*2,5322,596*2,592*1,880*1,0121,011*1,011*977*594594*626*
Net cash from operating activities4,252*2,8342,326*5,591*4,439*1,9543,917*6,311*1,974*1,1043,393*4,181*
Purchases of property and equipment330*284262*324*378*260361*320*370*347305*344*
Net cash from investing activities(1,346)*(19,618)(1,319)*(219)*(196)*(499)(473)*(1,702)*(1,458)*(131)(1,614)*(2,104)*
Share repurchases0*00*0*0*———year only———
Dividends paid1,160*1,2121,217*1,216*1,218*1,2581,262*1,263*1,262*1,2831,287*1,287*
Proceeds from long-term debtyear only12,8830*0*0*00*0*5,740*———
Repayments of long-term debt2,000*0395*2,478*0*0643*229*10,068*5001,220*0*
Net cash from financing activities967*14,644(4,023)*(3,852)*(1,642)*(993)(1,836)*(1,490)*(6,029)*(1,560)(2,630)*(1,222)*
Net change in cash3,951*(2,185)(3,038)*1,597*2,454*5281,736*3,115*(5,508)*(635)(861)*852*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingQuarter
Bristol Myers Squibb9,57413,0694,181*2.0B 10-QSep 30, 2026
Gilead Sciences6,4378,3005,035*1.2B 10-QSep 30, 2026
Vertex Pharmaceuticals4,9793,441643*253.5M 10-QSep 30, 2026
Zoetis1,4762,468655*413.2M 10-QJun 30, 2026
Pfizer1,82416,5835,375*5.7B 10-QSep 27, 2026
Amgen13,98910,0544,002*540.6M 10-QJun 30, 2026
Regeneron Pharmaceuticals3,6595,1161,783*not reported 10-QSep 30, 2026
Merck6,84916,6075,370*2.5B 10-QJun 30, 2026
Idexx Laboratories1981,214450*78.8M 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.